Synergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study.
Psychopharmacology July 1, 2024 Nathaniel A. Shanok, Sabrina Muzac, Leah Brown et al. 7 citations
Major Depressive Disorder (MDD) is a pervasive psychiatric condition effecting approximately 21 million adults in the U.S. (8.4%). An estimated 30-60% of patients are resistant to traditional treatment approaches (medications and talk-therapy), alluding to the need for additional options. Two promising treatment modalities include transcranial magnetic stimulation (TMS) and ketamine infusions;...